Health science reports · 2026
Resurgence of Ebola in the Democratic Republic of Congo: Lessons Learned and Future Directions.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Edward Majani, Ndagabwene Yacinter, Rajabu Martha Ernest, Ally Ally Hamisi, Mustapha Hawa, John Daniel Boniphace, Kisigo Fransisca
Аннотация
INTRODUCTION: The Democratic Republic of the Congo (DRC) remains the global epicenter of Ebola virus disease (EVD), having experienced more than 15 outbreaks since the disease was first identified in 1976. The 2025 resurgence in Kasai Province, caused by Orthoebolavirus zairense, resulted in over 60 confirmed cases and a case fatality rate exceeding 65%, highlighting persistent vulnerabilities in outbreak preparedness and response despite previous control successes. This article examines the drivers, response strategies, and public health implications of the 2025 Ebola outbreak.
METHODS: This perspective synthesizes evidence from publicly available reports, epidemiological updates, genomic surveillance findings, and guidance from national and international public health agencies to examine the epidemiological characteristics, health system challenges, response interventions, and lessons learned from the 2025 Ebola outbreak in the DRC.
RESULTS: Genomic evidence suggested viral persistence in human reservoirs as a likely source of the outbreak. Delayed diagnosis due to limited laboratory capacity, reagent shortages, and slow sample transportation impeded timely case confirmation. Sociocultural factors, including unsafe burial practices, vaccine hesitancy, and community mistrust, further complicated containment efforts. The outbreak overwhelmed fragile health systems, with inadequate isolation facilities and personal protective equipment contributing to healthcare worker infections, which accounted for 10% of reported cases. Coordinated national and international interventions, including emergency response activation, ring vaccination with the rVSVΔG-ZEBOV-GP (Ervebo) vaccine, enhanced surveillance, contact tracing, infection prevention and control measures, and technical support from global partners, were instrumental in interrupting transmission.
CONCLUSION: The 2025 Ebola outbreak demonstrates the continued threat of recurrent EVD in the DRC and underscores the need for resilient surveillance systems, decentralized laboratory capacity, sustained infection prevention and control measures, healthcare worker protection, meaningful community engagement, and strengthened regional collaboration. Integrating genomic surveillance and advancing vaccine research will be critical for improving epidemic preparedness and strengthening health security across Central Africa.
METHODS: This perspective synthesizes evidence from publicly available reports, epidemiological updates, genomic surveillance findings, and guidance from national and international public health agencies to examine the epidemiological characteristics, health system challenges, response interventions, and lessons learned from the 2025 Ebola outbreak in the DRC.
RESULTS: Genomic evidence suggested viral persistence in human reservoirs as a likely source of the outbreak. Delayed diagnosis due to limited laboratory capacity, reagent shortages, and slow sample transportation impeded timely case confirmation. Sociocultural factors, including unsafe burial practices, vaccine hesitancy, and community mistrust, further complicated containment efforts. The outbreak overwhelmed fragile health systems, with inadequate isolation facilities and personal protective equipment contributing to healthcare worker infections, which accounted for 10% of reported cases. Coordinated national and international interventions, including emergency response activation, ring vaccination with the rVSVΔG-ZEBOV-GP (Ervebo) vaccine, enhanced surveillance, contact tracing, infection prevention and control measures, and technical support from global partners, were instrumental in interrupting transmission.
CONCLUSION: The 2025 Ebola outbreak demonstrates the continued threat of recurrent EVD in the DRC and underscores the need for resilient surveillance systems, decentralized laboratory capacity, sustained infection prevention and control measures, healthcare worker protection, meaningful community engagement, and strengthened regional collaboration. Integrating genomic surveillance and advancing vaccine research will be critical for improving epidemic preparedness and strengthening health security across Central Africa.